By combining the molecular data of studies from the same cancer subtype and site of origin, the most frequently CCND1-mutated cancer subtypes were mantle cell lymphoma (34.5%, 10 of 29 cases), endometrial adenocacinoma (6.5%, 30 of 458 cases), multiple-myeloma (3.3%, 7 of 205 cases), colorectal carcinoma (1.1%, 23 of 2067 cases), melanoma (1.1%, 8 of 708 cases), skin non-melanoma cancer (1.1%, 2 of 177 cases) and uterine sarcoma (1.1%, 1 of 93 cases). Here, CCND1 is linked to plasma cell myeloma.